Table 4 Prognostic factors of disease-free survival of hepatocellular carcinoma

Age (> 65 years vs. 0–65 years)

0.920 (0.638–1.326)

0.655

1.013 (0.773–1.330)

0.923

Sex (female vs. male)

0.969 (0.623–1.509)

0.890

0.989 (0.717–1.364)

0.947

HBV (positive vs. negative)

1.241 (0.811–1.899)

0.319

0.929 (0.666–1.295)

0.663

HCV (positive vs. negative)

1.079 (0.748–1.556)

0.686

1.148 (0.875–1.505)

0.320

Child-Pugh (B vs. A)

1.310 (0.773–2.221)

0.316

1.413 (0.960–2.080)

0.079

AFP (>20 ng/ml vs. 0–20 ng/ml)

1.843 (1.272–2.670)

0.001

1.272 (0.834–1.939)

0.264

1.195 (0.914–1.564)

0.193

Tumor size (>5 cm vs. 0–5 cm)

3.253 (2.229–4.746)

<0.001

1.776 (1.165–2.708)

0.008

2.095 (1.599–2.746)

<0.001

1.626 (1.186–2.228)

0.003

Histologic grade (por vs. well/mod)

2.220 (1.510–3.265)

<0.001

1.165 (0.741–1.831)

0.508

1.298 (0.943-1.786)

0.110

Vascular invasion (present vs. absent)

4.465 (2.805–7.108)

<0.001

2.180 (1.279–3.714)

0.004

1.907 (1.443–2.519)

<0.001

1.156 (0.832–1.607)

0.387

Intrahepatic metastasis (present vs. absent)

4.730 (3.264–6.854)

<0.001

2.593 (1.689–3.981)

<0.001

3.989 (2.956–5.384)

<0.001

2.885 (2.030–4.099)

<0.001

Background liver (LC vs. non-LC)

1.124 (0.774–1.632)

0.540

1.357 (1.032–1.786)

0.029

1.496 (1.120-1.999)

0.006

SALL4 (positive vs. negative)

1.746 (1.088–2.801)

0.021

0.843 (0.457–1.554)

0.584

1.185 (0.801–1.753)

0.396

Cytokeratin 19 (positive vs. negative)

2.650 (1.746-4.002)

<0.001

1.832 (1.145-2.931)

0.012

1.662 (1.165–2.371)

0.005

1.606 (1.100–2.345)

0.014

EpCAM (positive vs. negative)

1.976 (1.260–3.097)

0.003

1.330 (0.794-2.230)

0.279

1.503 (1.037–2.180)

0.031

1.133 (0.768-1.672)

0.529